AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04025450
Drug: VRD
RxNorm normalized name: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human-Mus musculus monoclonal VRDN-001 γ1-chain), disulfide with human-Mus musculus monoclonal VRDN-001 κ-chain, dimer
DrugBank: Veligrotug (DB18976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
Trial: NCT01517711
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
Trial: NCT01120002
Drug: Tamibarotene
RxNorm normalized name: Tamibarotene
DrugBank: Tamibarotene (DB04942)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Two Tamibarotene 2 mg or placebo tablet per day, once daily.
Trial: NCT01834014
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT03236311
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03236311
Drug: 13N-ammonia
RxNorm normalized name: (13N)Ammonia
DrugBank: Ammonia (DB11118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03236311
Drug: 82Rubidium
RxNorm normalized name: rubidium
DrugBank: Rubidium (DB11346)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03719898
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatininb is administered in tablet form. It is to be taken until disease progression, unacceptable toxicity or completion of 24 cycles. patients may continue to take brigatininb beyond 24 cycles if they are benefiting from the drug
Trial: NCT04003012
Drug: EMLA
RxNorm normalized name: EMLA
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
Trial: NCT04003012
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine 1%
Trial: NCT04012931
Drug: Rilpivirine
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
Trial: NCT02900443
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04388878
Drug: PF-07054894
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral ascending doses
Trial: NCT00287963
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00287963
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01817985
Drug: GS-5816
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01517854
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg Revatio (sildenafil citrate) three times a day
Trial: NCT02304211
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
Trial: NCT04261166
Drug: A1
RxNorm normalized name: CA1P
DrugBank: OXI-4503 (DB05143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)
Trial: NCT04261166
Drug: A2
RxNorm normalized name: GA2
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)
Trial: NCT03851250
Drug: MRx-4DP0004
RxNorm normalized name: MRx-4DP0004
DrugBank: MRx-4DP0004 (DB15751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
Trial: NCT01206062
Drug: Intensive control of SBP
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the Intensive arm have a goal of SBP \<120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies.
Trial: NCT03040596
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
Trial: NCT03784547
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: already described
Trial: NCT04261166
Drug: A3
RxNorm normalized name: PA3-17
DrugBank: PA3-17 (DB18569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)
Trial: NCT04261166
Drug: A4
RxNorm normalized name: CA4
DrugBank: Combretastatin A4 (DB14680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)
Trial: NCT04261166
Drug: B1
RxNorm normalized name: KB109
DrugBank: KB109 (DB16531)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)
Trial: NCT04261166
Drug: B2
RxNorm normalized name: B27PD
DrugBank: B27PD (DB16289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)
Trial: NCT04261166
Drug: B3
RxNorm normalized name: KB3305
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablets. CBD 40 mg (1 tablet)
Trial: NCT01140581
Drug: DRONEDARONE
RxNorm normalized name: Dronedarone
DrugBank: Dronedarone (DB04855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
Trial: NCT04261166
Drug: B4
RxNorm normalized name: LTB4
DrugBank: Leukotriene B4 (DB12961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablets. CBD 40 mg (1 tablet)
Trial: NCT01692717
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg
Trial: NCT03190005
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
Trial: NCT02566928
Drug: 2% mupirocin ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
Trial: NCT01097577
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
Trial: NCT01366547
Drug: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
Trial: NCT01366547
Drug: Dolutegravir 50 mg
RxNorm normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
Trial: NCT01366547
Drug: abacavir 600 mg/lamivudine 300 mg
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
Trial: NCT04298918
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive oral venetoclax.
Trial: NCT04298918
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive intravenous (IV) trastuzumab emtansine.
Trial: NCT03235739
Drug: Naloxegol 25 MG
RxNorm normalized name: naloxegol 25 MG
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Naloxegol 25 MG
Trial: NCT00128856
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00128856
Drug: Adriamycine
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00128856
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02960828
Drug: intravitreal Anti-VEGF injection
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
Trial: NCT01066143
Drug: Seroquel XR
RxNorm normalized name: Seroquel XR
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
Trial: NCT02064530
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21 ml 0.5 %bupivacaine is applied interfasially
Trial: NCT02064530
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
Trial: NCT02064530
Drug: serum physiologic
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 ml serum physiologic is applied interfasially
Trial: NCT03006705
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Trial: NCT03006705
Drug: Tegafur-gimeracil-oteracil potassium
RxNorm normalized name: tegafur
DrugBank: Oteracil (DB03209)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
Trial: NCT03006705
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Trial: NCT02982356
Drug: Potassium Chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02632344
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
Trial: NCT00006682
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 70mg/m2 on day 1 of every 21-day cycle
Trial: NCT00006682
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle
Trial: NCT00467896
Drug: Iloprost PD-6
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
Trial: NCT05288400
Drug: Norvasc 5mg tablet
RxNorm normalized name: Norvasc 5mg Tablet
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norvasc (amlodipine) 5mg, 1 tablet/day
Trial: NCT05288400
Drug: Concor 5mg tablet
RxNorm normalized name: Loncor
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concor (bisoprolol fumarate) 5mg, 1 tablet/day
Trial: NCT05288400
Drug: Coversyl 5mg tablet
RxNorm normalized name: Ioversol
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coversyl (perindopril arginine) 5mg, 1 tablet/day
Trial: NCT00467896
Drug: Iloprost PD-15
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
Trial: NCT02847650
Drug: PF-06649751
RxNorm normalized name: PF-06649751
DrugBank: Tavapadon (DB14899)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02562378
Drug: Trastuzumab and non-pegylated liposomal doxorubicin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 Cohorts (3+3 design):~Cohort 1- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2) IV~Cohort 2- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (50 mg/m2) IV~Cohort 3- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (60 mg/m2) IV
Trial: NCT04503603
Drug: Lanadelumab
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
Trial: NCT01124175
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg Tablets
Trial: NCT00000294
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03057106
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MEDI4736
Trial: NCT03057106
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab
Trial: NCT03057106
Drug: Platinum-Based Drug
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed, cisplatin, carboplatin or gemcitibine
Trial: NCT03448068
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated.
Trial: NCT02711449
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
Trial: NCT00825500
Drug: Inhaled Loxapine 1.25 mg
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Loxapine 1.25 mg, single dose
Trial: NCT00825500
Drug: Inhaled Loxapine 2.5 mg
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Loxapine 1.25 mg, single dose
Trial: NCT00621699
Drug: 1 tablet Ezetrol(R) + 1 capsules Prograf(R)
RxNorm normalized name: (R)-LACOSAMIDE 1
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Trial: NCT01528111
Drug: LX7101 (0.25%)
DrugBank: LX-7101 (DB16009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 0.25% LX7101
Trial: NCT03844984
Drug: ketamine full dose
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
Trial: NCT03844984
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This group will receive midazolam 0.05 mg/Kg
Trial: NCT03844984
Drug: ketamine half dose
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
Trial: NCT03844984
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
Trial: NCT02940535
Drug: Diphereline (Triptorelin embonate)
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02940535
Drug: Decapeptyl (Triptorelin)
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02940535
Drug: human menopausal gonadotropin
RxNorm normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02940535
Drug: human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02605187
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 600mg po one time within 1 hour of delivery
Trial: NCT02605187
Drug: Morphine (low)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine dose 50mcg
Trial: NCT02605187
Drug: Morphine (med)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine dose 150mcg
Trial: NCT02605187
Drug: Morphine (high)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 300mcg
Trial: NCT02159729
Drug: ATX-101 (1 mg/cm^2)
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Trial: NCT02159729
Drug: ATX-101 (2 mg/cm^2)
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Trial: NCT02159729
Drug: ATX-101 (4 mg/cm^2)
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Trial: NCT01358344
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg delayed-release tablet administered orally in the morning of Days 1-7
Trial: NCT01358344
Drug: SCH 530348 (high percentage)
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg tablet containing \~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
Trial: NCT01358344
Drug: SCH 530348 (standard percentage)
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg tablet containing \~23% API as free base (STANDARD) administered orally on the morning of Day 5
Trial: NCT01344291
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin is prescribed to new cases of hyperprolactinoma
Trial: NCT02325960
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.